Clinical outcomes of antimicrobial resistance in cancer patients: a systematic review of multivariable models

[1] Jarlier V(2019)Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates of acquired resistance in Gram-negative species causing bacteraemia, EU/EEA, 2016 Eurosurveillance 24 1800538-66

[2] Högberg LD(2019)Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis Lancet Infect Dis 19 56-210

[3] Heuer OE(2014)Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact Curr Opin Infect Dis 27 200-83

[4] Campos J(2017)Infections in cancer patients with solid tumors: a review Infect Dis Ther 6 69-504

[5] Eckmanns T(2021)Antibiotic resistance in the patient with cancer: escalating challenges and paths forward CA Cancer J Clin 71 488-3051

[6] Giske CG(2013)Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research PLOS Med 10 e1001380380-2644

[7] Cassini A(2013)Prognosis Research Strategy (PROGRESS) 3: prognostic Model Research PLOS Med 10 e1001381-50

[8] Högberg LD(2000)The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients J Clin Oncol 18 3038-1657

[9] Plachouras D(1992)Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy Antimicrob Agents Chemother 36 2639-504

[10] Quattrocchi A(1961)Factors of risk in the development of coronary heart disease–six year follow-up experience the framingham study Ann Intern Med 55 33-245

[1] Jarlier V(2019)Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates of acquired resistance in Gram-negative species causing bacteraemia, EU/EEA, 2016 Eurosurveillance 24 1800538-66

[2] Högberg LD(2019)Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis Lancet Infect Dis 19 56-210

[3] Heuer OE(2014)Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact Curr Opin Infect Dis 27 200-83

[4] Campos J(2017)Infections in cancer patients with solid tumors: a review Infect Dis Ther 6 69-504

[5] Eckmanns T(2021)Antibiotic resistance in the patient with cancer: escalating challenges and paths forward CA Cancer J Clin 71 488-3051

[6] Giske CG(2013)Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research PLOS Med 10 e1001380380-2644

[7] Cassini A(2013)Prognosis Research Strategy (PROGRESS) 3: prognostic Model Research PLOS Med 10 e1001381-50

[8] Högberg LD(2000)The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients J Clin Oncol 18 3038-1657

[9] Plachouras D(1992)Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy Antimicrob Agents Chemother 36 2639-504

[10] Quattrocchi A(1961)Factors of risk in the development of coronary heart disease–six year follow-up experience the framingham study Ann Intern Med 55 33-245